Core Viewpoint - LAE102, developed by the company, shows promising preliminary results in a Phase I multi-dose escalation study for obesity treatment in China, indicating potential for effective weight management [1] Group 1: Study Overview - The MAD study is a randomized, double-blind, placebo-controlled trial aimed at assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE102 in overweight/obese subjects [1] - The study included participants with an average Body Mass Index (BMI) of 29.4 kg/m² and involved three dose escalation groups (2 mg/kg, 4 mg/kg, and 6 mg/kg), with weekly subcutaneous administration over four weeks [1] Group 2: Preliminary Results - Initial results indicate a positive trend in muscle gain and fat loss, with the 6 mg/kg dose group showing an average lean body mass increase of 1.7% compared to baseline [1] - Adjusted for the placebo group, the average lean body mass increase reached 4.6%, while the average fat mass decreased by 3.6% [1]
来凯医药：LAE102的I期临床MAD研究取得积极初步结果